Q-omics provides the consensus-scored LINC02584 profile across patient tissues and cancer cell-line models. LINC02584 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC02584 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, LINC02584 RNA expression shows 8,033 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight KIRP, HNSC, and PAAD as cancer lineages where LINC02584 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02584 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02584 survival associations across molecular data types. LINC02584 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02584 RNA expression–survival associations across cancer types. High LINC02584 expression shows unfavorable associations in KIRP, COAD, HNSC, STAD and LGG, but favorable associations in UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC02584 RNA expression.
This table summarizes LINC02584 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02584. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02584 shows lower tumor expression in BRCA and higher tumor expression in HNSC, COAD, BLCA, STAD and THCA. The HNSC box plot shows higher LINC02584 RNA expression in tumor versus normal tissue (log2 FC = +0.528, t-test p < 0.001).
This table shows molecular features associated with LINC02584 in patient tissues and cancer cell lines. In patient samples, LINC02584 shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set.
